

# Pierre Wolkenstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1530295/publications.pdf>

Version: 2024-02-01

184  
papers

10,333  
citations

38742

50  
h-index

36028

97  
g-index

198  
all docs

198  
docs citations

198  
times ranked

6968  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lupus erythematosus and epidermal necrolysis: a case series of 16 patients. British Journal of Dermatology, 2022, 186, 372-374.	1.5	3
2	Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience. European Journal of Medical Genetics, 2022, 65, 104386.	1.3	11
3	Dermatological emergency unit, dayâ€care hospital and consultations in time of COVIDâ€19: the impact of teledermatology. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
4	Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis. British Journal of Dermatology, 2022, 186, 1037-1039.	1.5	2
5	Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 739-743.	2.4	0
6	ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. European Journal of Human Genetics, 2022, 30, 812-817.	2.8	11
7	Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase. Pharmacoepidemiology and Drug Safety, 2022, 31, 434-441.	1.9	2
8	Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1359-1366.	2.4	7
9	Bullous pemphigoid: Three main clusters defining 3 outcome profiles. Journal of the American Academy of Dermatology, 2022, 87, 359-365.	1.2	7
10	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Scientific Reports, 2022, 12, 7140.	3.3	45
11	Involvement of smallâ€diameter nerve fibres in longâ€term chronic pain after Stevensâ€Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e218-e221.	2.4	2
12	A process modelling approach to assess the impact of teledermatology deployment onto the skin tumor care pathway. International Journal of Medical Informatics, 2021, 146, 104361.	3.3	10
13	Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases. Contact Dermatitis, 2021, 84, 280-282.	1.4	4
14	Chronic pain: a longâ€term sequela of epidermal necrolysis (Stevensâ€Johnson syndrome/toxic epidermal) Tj ETQq0 0 0 rgBT /Overlock of Dermatology and Venereology, 2021, 35, 188-194.	2.4	10
15	[18F]FDG Positron emission tomography with whole body magnetic resonance imaging ([18F]FDG-PET/MRI) as a diagnosis tool in Schwannomatosis. Orphanet Journal of Rare Diseases, 2021, 16, 49.	2.7	1
16	The Heart in Neurofibromatosis 1. , 2021, , 87-109.		0
17	Essential oils as potential triggers for bullous pemphigoid? A report of two patients. European Journal of Dermatology, 2021, 31, 92-93.	0.6	2
18	Face transplantation: A longitudinal histological study focusing on chronic active and mucosal rejection in a series with long-term follow-up. American Journal of Transplantation, 2021, 21, 3088-3100.	4.7	6

#	ARTICLE	IF	CITATIONS
19	Identifying challenges in neurofibromatosis: a modified Delphi procedure. <i>European Journal of Human Genetics</i> , 2021, 29, 1625-1633.	2.8	7
20	Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports. <i>Therapie</i> , 2021, , .	1.0	4
21	Combined Methotrexate and Alitretinoin for the treatment of difficult-to-treat generalized prurigo nodularis: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e516-e519.	2.4	5
22	Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus. <i>British Journal of Dermatology</i> , 2021, 185, 616-626.	1.5	22
23	Which patients present to dermatologic emergencies? A survey on 1561 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e583-e585.	2.4	1
24	Non-acral skin manifestations during the COVID-19 epidemic: COVIDSKIN study by the French Society of Dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e539-e541.	2.4	3
25	Lymphoproliferative malignancies in patients with neurofibromatosis 1. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 230.	2.7	5
26	Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1569-1576.	2.4	4
27	Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms. <i>European Journal of Dermatology</i> , 2021, 31, 372-380.	0.6	7
28	Severe Phenotype in Patients with Large Deletions of NF1. <i>Cancers</i> , 2021, 13, 2963.	3.7	15
29	Pityriasis lichenoides: a clinical and pathological case series of 49 patients with an emphasis on follow-up. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1561-1566.	1.3	1
30	Patch tests in non-immediate cutaneous adverse drug reactions: the importance of late readings on day 4. <i>Contact Dermatitis</i> , 2021, , .	1.4	5
31	Missed Diagnosis of Epilepsy-Associated Scald Burns: Two Cases Initially Diagnosed as Bullous Dermatitis. <i>Journal of Burn Care and Research</i> , 2021, 42, 569-572.	0.4	0
32	Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. <i>British Journal of Dermatology</i> , 2020, 182, 247-248.	1.5	16
33	Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e48-e52.	1.1	11
34	Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 787-794.	2.4	12
35	Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. <i>British Journal of Dermatology</i> , 2020, 182, 916-926.	1.5	24
36	Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf .</i> <i>Dermatology</i> , 2020, 182, 618-624.	1.5	29

#	ARTICLE	IF	CITATIONS
37	Individual and hospital level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012–2016. <i>British Journal of Dermatology</i> , 2020, 182, 900-906.	1.5	13
38	Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. <i>Genetics in Medicine</i> , 2020, 22, 398-406.	2.4	26
39	Cutaneous tests and interest of iobitridol in non immediate hypersensitivity to contrast media: a case series of 43 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e178-e180.	2.4	5
40	Neurofibromatosis I and multiple sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 186.	2.7	7
41	Iloprost: a potential alternative for skin graft resistant hypertensive leg ulcer. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e726-e728.	2.4	2
42	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 843-852.	5.6	12
43	Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 37.	2.7	96
44	Strong reactions to diltiazem patch tests: Plea for a low concentration. <i>Contact Dermatitis</i> , 2020, 83, 224-225.	1.4	4
45	Hair follicle stem cell replication stress drives IFI16/STING-dependent inflammation in hidradenitis suppurativa. <i>Journal of Clinical Investigation</i> , 2020, 130, 3777-3790.	8.2	35
46	Medical Follow-Up in Neurofibromatosis Type 1. , 2020, , 273-304.		0
47	Beard dermatitis induced by coloration. <i>Contact Dermatitis</i> , 2019, 81, 471-473.	1.4	4
48	Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a Trial. <i>Journal of Investigative Dermatology</i> , 2019, 139, 718-720.	0.7	19
49	Cervical cutaneous sclerosis: the stomach is not far from the skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e177-e179.	2.4	0
50	Acute generalized exanthematous pustulosis and epidermal necrolysis differ in innate cytokine patterns. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1258-1261.	2.9	4
51	Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: A retrospective observational cohort study of 98 cases. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 342-347.	1.2	11
52	Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae. <i>British Journal of Dermatology</i> , 2019, 181, 421-422.	1.5	9
53	Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1453-1455.	1.2	14
54	Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 286.	2.7	25

#	ARTICLE	IF	CITATIONS
55	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with <i>de novo</i> carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 886-896.	5.1	22
56	Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. <i>British Journal of Dermatology</i> , 2019, 180, 1234-1235.	1.5	10
57	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1344-1346.	3.8	0
58	Severe contact allergy to mupirocin in a polysensitized patient. <i>Contact Dermatitis</i> , 2019, 80, 397-398.	1.4	11
59	Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with <i>Nf1</i> Knockout in Boundary Cap Cells. <i>Cancer Discovery</i> , 2019, 9, 130-147.	9.4	57
60	Breast cancer risk in neurofibromatosis type 1 is a function of the type of <i>NF1</i> gene mutation: a new genotype-phenotype correlation. <i>Journal of Medical Genetics</i> , 2019, 56, 209-219.	3.2	26
61	Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. <i>British Journal of Dermatology</i> , 2019, 180, 1206-1213.	1.5	29
62	Bladder Dysfunction in Children with Neurofibromatosis Type I: Report of Four Cases and Review of the Literature. <i>Urologia Internationalis</i> , 2018, 100, 339-345.	1.3	8
63	Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that "toxic" epidermal necrolysis can be "non-toxic". <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e360-e361.	1.4	7
64	Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients Exposed/Unexposed and Propensity Score-Matched Analyses. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1293-1300.	0.7	41
65	High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case series. <i>Current Medical Research and Opinion</i> , 2018, 34, 887-891.	1.9	9
66	Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. <i>JAMA Dermatology</i> , 2018, 154, 487.	4.1	8
67	Severe cutaneous adverse reactions due to inappropriate medication use. <i>British Journal of Dermatology</i> , 2018, 179, 329-336.	1.5	17
68	Stevens-Johnson Syndrome During Pregnancy. <i>JAMA Dermatology</i> , 2018, 154, 224.	4.1	3
69	Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.7	54
70	Clinical and histologic features of <i>Mycoplasma pneumoniae</i> -related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 110-117.	1.2	41
71	Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 298-306.	2.4	115
72	Severe sequelae of erythema multiforme: three cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e34-e36.	2.4	9

#	ARTICLE	IF	CITATIONS
73	Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 437-440.	2.4	30
74	Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients. Human Pathology, 2018, 71, 100-108.	2.0	8
75	Acne across Europe: an online survey on perceptions and management of acne. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 463-466.	2.4	15
76	Very late sensitization to parabens induced by repeated applications of an anaesthetic therapeutic plaster to non-damaged skin. Contact Dermatitis, 2018, 79, 194-195.	1.4	5
77	A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices. British Journal of Dermatology, 2018, 179, 1009-1011.	1.5	7
78	Primary cutaneous mucormycosis as a complication of erosive dermatitis: two cases. European Journal of Dermatology, 2018, 28, 227-229.	0.6	2
79	The biology of cutaneous neurofibromas. Neurology, 2018, 91, S14-S20.	1.1	27
80	Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis. JAMA Dermatology, 2018, 154, 1017.	4.1	70
81	Association Between Severe Acute Contact Dermatitis Due to <i>Nigella sativa</i> Oil and Epidermal Apoptosis. JAMA Dermatology, 2018, 154, 1062.	4.1	22
82	Creating a comprehensive research strategy for cutaneous neurofibromas. Neurology, 2018, 91, S1-S4.	1.1	11
83	Cutaneous neurofibromas. Neurology, 2018, 91, S5-S13.	1.1	79
84	Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing. British Journal of Dermatology, 2018, 179, 978-979.	1.5	7
85	Urgences dermatologiques en réanimation : infections nosocomiales de la peau et des parties molles et toxidermies graves. Médecine Intensive Réanimation, 2018, 27, 461-474.	0.0	0
86	Republication de : Traitement des toxidermies graves. Journal Européen Des Urgences Et De Réanimation, 2018, 30, 161-171.	0.1	0
87	Febrile ulceronecrotic Mucha Habermann disease mimicking aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: a diagnostic challenge. European Journal of Dermatology, 2018, 28, 834-835.	0.6	7
88	Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone. Journal of Investigative Dermatology, 2017, 137, 1179-1181.	0.7	3
89	Facial transplantation: facing the limits, planning the future. Lancet, The, 2017, 389, 1293-1294.	13.7	6
90	Severe cutaneous adverse reactions to drugs. Lancet, The, 2017, 390, 1996-2011.	13.7	293

#	ARTICLE	IF	CITATIONS
91	Skin biopsy polymerase chain reaction for rapid microbiological diagnosis in patients with purpura fulminans. <i>British Journal of Dermatology</i> , 2017, 177, e154-e155.	1.5	5
92	Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. <i>British Journal of Dermatology</i> , 2017, 177, 212-222.	1.5	42
93	First case of contact dermatitis caused by hydroxypropyl tetrahydropyrantriol used in an anti-aging cream. <i>Contact Dermatitis</i> , 2017, 77, 60-61.	1.4	2
94	Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. <i>Contact Dermatitis</i> , 2017, 77, 297-302.	1.4	29
95	Self-diagnosed drug allergies: the belief of patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e524-e526.	2.4	1
96	Hemostasis and Type 1 Neurofibromatosis. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2017, 5, e1414.	0.6	3
97	Dermatitis herpetiformis and bone mineral density: analysis of a French cohort of 53 patients. <i>European Journal of Dermatology</i> , 2017, 27, 353-358.	0.6	5
98	Renal replacement therapy during Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients. <i>British Journal of Dermatology</i> , 2017, 176, 1370-1372.	1.5	10
99	Dermatological emergencies: evolution from 2008 to 2014 and perspectives. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 274-279.	2.4	15
100	Agreement Between Self-reported Inflammatory Skin Disorders and Dermatologists'™ Diagnosis: A Cross-sectional Diagnostic Study. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1243-1244.	1.3	12
101	Epidemiology of fragile skin: Internet-based surveys in Mexico and Russia. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 221-228.	1.8	3
102	Clinical Characteristics of Pruritus in Neurofibromatosis 1. <i>Acta Dermato-Venereologica</i> , 2016, 96, 398-399.	1.3	28
103	Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant. <i>Medicine (United States)</i> , 2016, 95, e3033.	1.0	63
104	Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1140-1143.	2.4	15
105	Neurofibromatosis type 1: neurofibromas and sex. <i>British Journal of Dermatology</i> , 2016, 174, 402-404.	1.5	10
106	Antitumour necrosis factor- $\pm$ therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. <i>British Journal of Dermatology</i> , 2016, 174, 667-670.	1.5	18
107	Toxic epidermal necrolysis: The past, the guidelines and challenges for the future. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, 733-735.	1.0	4
108	Patient-hospital communication: A platform to improve outpatient chemotherapy. , 2016, , .		4

#	ARTICLE	IF	CITATIONS
109	Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2016, 136, 1768-1780.	0.7	129
110	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 2016, 87, S40-8.	1.1	23
111	Toxic epidermal necrolysis: the past, the guidelines and challenges for the future. British Journal of Dermatology, 2016, 174, 1171-1173.	1.5	5
112	Facial Scars following Toxic Epidermal Necrolysis: Role of Adnexal Involvement?. Dermatology, 2016, 232, 220-223.	2.1	7
113	Pemphigoid gestationis revealing a denial of pregnancy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1411-1413.	2.4	3
114	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget, 2016, 7, 35753-35767.	1.8	46
115	Necrotizing fasciitis of the thigh revealing a Crohn's disease. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1648-1649.	2.4	3
116	Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. British Journal of Dermatology, 2015, 173, 50-58.	1.5	104
117	First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical Corticosteroids. JAMA Dermatology, 2015, 151, 200.	4.1	48
118	Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. British Journal of Dermatology, 2015, 173, 1142-1155.	1.5	132
119	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2015, 151, 302.	4.1	31
120	NF1 single and multi-exons copy number variations in neurofibromatosis type 1. Journal of Human Genetics, 2015, 60, 221-224.	2.3	15
121	Therapeutic management of DRESS: A retrospective study of 38 cases. Journal of the American Academy of Dermatology, 2015, 72, 246-252.	1.2	110
122	Nodules on a sternotomy scar. Lancet Infectious Diseases, The, 2015, 15, 986.	9.1	2
123	Consequences of Acne on Stress, Fatigue, Sleep Disorders and Sexual Activity: A Population-based Study. Acta Dermato-Venereologica, 2015, 95, 485-488.	1.3	38
124	Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. British Journal of Dermatology, 2015, 172, 400-405.	1.5	26
125	Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?. European Journal of Human Genetics, 2015, 23, 596-601.	2.8	97
126	Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre. British Journal of Dermatology, 2015, 172, 1455-1457.	1.5	34



#	ARTICLE	IF	CITATIONS
127	Smoking and Dietary Factors Associated with Moderate-to-Severe Acne in French Adolescents and Young Adults: Results of a Survey Using a Representative Sample. <i>Dermatology</i> , 2015, 230, 34-39.	2.1	48
128	Contact dermatitis caused by ascorbyl tetraisopalmitate in a cream used for the management of atopic dermatitis. <i>Contact Dermatitis</i> , 2014, 71, 60-61.	1.4	15
129	Acute Respiratory Failure in Patients With Toxic Epidermal Necrolysis. <i>Critical Care Medicine</i> , 2014, 42, 118-128.	0.9	72
130	Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by d-penicillamine in Wilson disease. <i>British Journal of Dermatology</i> , 2014, 171, 1574-1576.	1.5	7
131	mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. <i>Neuro-Oncology</i> , 2014, 16, 493-504.	1.2	67
132	Sirolimus Improves Pain in NF1 Patients With Severe Plexiform Neurofibromas. <i>Pediatrics</i> , 2014, 133, e1792-e1797.	2.1	29
133	Severe Cutaneous Adverse Reactions to Drugs: From Patients to the National Office for Compensation of Medical Accidents. <i>Dermatology</i> , 2014, 228, 338-343.	2.1	5
134	Dermatological emergencies: a comparative study of activity in 2000 and 2010. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 916-918.	2.4	26
135	Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. <i>British Journal of Dermatology</i> , 2013, 169, 1223-1232.	1.5	121
136	Prognostic value of histologic features of toxic epidermal necrolysis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e29-e35.	1.2	34
137	<i>NF1</i> Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience. <i>Human Mutation</i> , 2013, 34, 1510-1518.	2.5	140
138	Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1506-1511.	0.7	187
139	Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. <i>British Journal of Dermatology</i> , 2013, 169, 1041-1048.	1.5	99
140	The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. <i>British Journal of Dermatology</i> , 2012, 167, 555-562.	1.5	64
141	Neurofibromatosis type 1: from genotype to phenotype. <i>Journal of Medical Genetics</i> , 2012, 49, 483-489.	3.2	133
142	Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-sectional study. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 62.	2.7	20
143	Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist?. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 72.	2.7	96
144	Mortality Associated with Neurofibromatosis 1: A Cohort Study of 1895 Patients in 1980-2006 in France. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 18.	2.7	96

#	ARTICLE	IF	CITATIONS
145	At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control Study. Orphanet Journal of Rare Diseases, 2011, 6, 51.	2.7	18
146	S100B and neurofibromin immunostaining and Xa€inactivation patterns of lasera€microdissected cells indicate a multicellular origin of some NF1a€associated neurofibromas. Journal of Neuroscience Research, 2011, 89, 1451-1460.	2.9	5
147	Evolving Pattern with Age of Cutaneous Signs in Neurofibromatosis Type 1: A Cross-Sectional Study of 728 Patients. Dermatology, 2011, 222, 269-273.	2.1	64
148	Different Patterns of Mast Cells Distinguish Diffuse from Encapsulated Neurofibromas in Patients with Neurofibromatosis 1. Journal of Histochemistry and Cytochemistry, 2011, 59, 584-590.	2.5	29
149	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. Journal of the National Cancer Institute, 2011, 103, 1713-1722.	6.3	106
150	NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Human Mutation, 2010, 31, E1506-E1518.	2.5	208
151	Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology, 2010, 163, 847-853.	1.5	204
152	NF-1Score: A Prediction Score for Internal Neurofibromas in Neurofibromatosis-1. Journal of Investigative Dermatology, 2010, 130, 2173-2178.	0.7	31
153	Bacteremia in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Medicine (United States), 2010, 89, 28-36.	1.0	80
154	Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Human Molecular Genetics, 2009, 18, 2768-2778.	2.9	129
155	SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. Journal of Medical Genetics, 2009, 46, 425-430.	3.2	103
156	Health-Related Quality of Life in Patients with Neurofibromatosis Type 1. Dermatology, 2009, 218, 215-220.	2.1	73
157	Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey. Dermatology, 2009, 218, 103-109.	2.1	76
158	Combination Therapy with Clindamycin and Rifampicin for Hidradenitis Suppurativa: A Series of 116 Consecutive Patients. Dermatology, 2009, 219, 148-154.	2.1	222
159	Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases. British Journal of Dermatology, 2009, 160, 844-848.	1.5	57
160	Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH. Journal of Molecular Diagnostics, 2009, 11, 524-529.	2.8	31
161	Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. Journal of the American Academy of Dermatology, 2009, 61, 51-57.	1.2	244
162	Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. Journal of the American Academy of Dermatology, 2008, 59, 596-601.	1.2	559

#	ARTICLE	IF	CITATIONS
163	Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. <i>Lancet, The</i> , 2008, 372, 639-645.	13.7	329
164	Quality of life impairment in hidradenitis suppurativa: A study of 61 cases. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 621-623.	1.2	325
165	Impact of neurofibromatosis 1 on Quality of Life: A cross-sectional study of 176 American cases. <i>American Journal of Medical Genetics, Part A</i> , 2006, 140A, 1893-1898.	1.2	121
166	Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1. <i>British Journal of Dermatology</i> , 2005, 153, 79-82.	1.5	104
167	Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients. <i>American Journal of Medical Genetics, Part A</i> , 2005, 132A, 49-53.	1.2	73
168	Association between benign and malignant peripheral nerve sheath tumors in NF1. <i>Neurology</i> , 2005, 65, 205-211.	1.1	274
169	Neurofibromatosis 1-associated neuropathies: a reappraisal. <i>Brain</i> , 2004, 127, 1993-2009.	7.6	61
170	Elevated Risk for MPNST in NF1 Microdeletion Patients. <i>American Journal of Human Genetics</i> , 2003, 72, 1288-1292.	6.2	271
171	Clinical Risk Factors for Mortality in Patients With Neurofibromatosis 1. <i>Archives of Dermatology</i> , 2003, 139, 187-91.	1.4	47
172	Visibility of Neurofibromatosis 1 and Psychiatric Morbidity. <i>Archives of Dermatology</i> , 2003, 139, 103.	1.4	24
173	Quality-of-Life Impairment in Neurofibromatosis Type 1. <i>Archives of Dermatology</i> , 2001, 137, 1421-5.	1.4	177
174	SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2000, 115, 149-153.	0.7	850
175	Neurological complications of neurofibromatosis type 1 in adulthood. <i>Brain</i> , 1999, 122, 473-481.	7.6	245
176	Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. <i>Lancet, The</i> , 1998, 352, 1586-1589.	13.7	414
177	Schwannomatosis: A Clinical Entity Distinct from Neurofibromatosis Type 2. <i>Dermatology</i> , 1997, 195, 228-231.	2.1	37
178	Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. <i>Intensive Care Medicine</i> , 1997, 23, 1237-44.	8.2	163
179	Vulvovaginal sequelae in toxic epidermal necrolysis. <i>Journal of reproductive medicine, The</i> , 1997, 42, 153-6.	0.2	23
180	Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Contact Dermatitis</i> , 1996, 35, 234-236.	1.4	260

#	ARTICLE	IF	CITATIONS
181	Usefulness of Screening Investigations in Neurofibromatosis Type 1. Archives of Dermatology, 1996, 132, 1333.	1.4	42
182	Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Archives of Dermatology, 1996, 132, 1333-1336.	1.4	42
183	Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Archives of Dermatology, 1996, 132, 1333-6.	1.4	8
184	Erythema multiforme associated with anti-epi-plakin antibodies: a multicentric retrospective case series. Journal of the European Academy of Dermatology and Venereology, 0, , .	2.4	3